Late Lim Seong-gi, Chairman of Hanmi Pharm, Ranked No.1 in Pharmaceutical and Bio Industry Compensation Last Year... Impact of Retirement Income

Chairman Seo Jung-jin of Celltrion Receives 6.9 Billion KRW
Executive Director Lee Han-gi of Celltrion Healthcare Receives 6.4 Billion KRW

[Asia Economy Reporter Eunmo Koo] It has been revealed that the late Seong-gi Lim, chairman of Hanmi Pharmaceutical Group who passed away last year, received the highest compensation among executives of major domestic pharmaceutical and bio companies.

According to the business reports of major pharmaceutical and bio companies on the 18th, the late Chairman Seong-gi Lim of Hanmi Pharmaceutical received 9.545 billion KRW in compensation last year. His salary was 518 million KRW, and retirement income was 9.027 billion KRW. Chairman Lim also received 2.24 billion KRW including retirement pay from Hanmi Science, the holding company of Hanmi Pharmaceutical. His salary was 578 million KRW, and retirement pay was 1.662 billion KRW. The total compensation Chairman Lim received from the two affiliates was 11.785 billion KRW.

Seo Jung-jin, honorary chairman of Celltrion Group, received a total of 6.942 billion KRW in compensation from Celltrion and Celltrion Healthcare. He received 3.186 billion KRW from Celltrion and 3.756 billion KRW from Celltrion Healthcare.

Executive Director Han-gi Lee of Celltrion Healthcare received 6.468 billion KRW in compensation last year. His salary was 163 million KRW, but the gain from exercising stock options amounted to 6.242 billion KRW. The remaining 63 million KRW was a bonus.

Several employees at Celltrion and Celltrion Healthcare received high compensation through exercising stock options. At Celltrion, one manager-level employee earned 4.182 billion KRW from exercising stock options, and at Celltrion Healthcare, two deputy manager-level employees received between 3.667 billion KRW and 5.963 billion KRW through stock option exercises. Advisor Man-hoon Kim of Celltrion Healthcare also received 3.42 billion KRW thanks to gains from exercising stock options.

Kim Tae-han, chairman of the board of Samsung Biologics who stepped down as CEO last December, received 2.783 billion KRW in compensation from the company. Heo Il-seop, chairman of Green Cross, received 1.188 billion KRW from Green Cross and 778 million KRW from Green Cross Holdings, totaling 1.966 billion KRW from the two affiliates.

Among diagnostic kit companies, CEO Jong-yoon Cheon of Seegene received 1.531 billion KRW in compensation last year. In addition, Chairman Jang-han Lee of the holding company of Chong Kun Dang, Chong Kun Dang Holdings, received 1.286 billion KRW, and CEO Woo-sung Ki of Celltrion received 1.036 billion KRW in compensation.